Required early complement activation in contact sensitivity with generation of local C5-dependent chemotactic activity, and late T cell interferon γ: A possible initiating role of B cells

Journal of Experimental Medicine

Volumn 186, Issue 7, 1997, Pages 1015-1026

  Tsuji, Ryohei F ^a   Geba, Gregory P ^b   Wang, Yi ^c   Kawamoto, Keiko ^d   Matis, Louis A ^c   Askenase, Philip W ^b  

^a Noda Institute for Scientific Research   (Japan)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ALEXION PHARMACEUTICALS   (United States)

^d Osaka Prefecture University   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; GAMMA INTERFERON; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CHEMOTAXIS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; FEMALE; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CHEMOTACTIC FACTORS, MACROPHAGE; CHEMOTAXIS; COBRA VENOMS; COMPLEMENT ACTIVATION; COMPLEMENT C5; COMPLEMENT INACTIVATOR PROTEINS; DERMATITIS, CONTACT; FEMALE; HYPERSENSITIVITY, DELAYED; INTERFERON TYPE II; MACROPHAGES; MICE; MICE, INBRED STRAINS; RECEPTORS, COMPLEMENT; RECOMBINANT PROTEINS; SKIN; T-LYMPHOCYTES;

EID: 0030779117     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.186.7.1015     Document Type: Article

References (55)

1. Fearon, D.T., and R.M. Locksley. 1996. The instructive role of innate immunity in the acquired immune response. Science (Wash. DC). 272:50-54.
2. Scharton-Kersten, T., and P. Scott. 1995. The role of the innate immune response in Th1 cell development following Leishmania major infection. J. Leukocyte Biol. 57:515-522.
3. + T cells through IL-12 produced by Listeria-induced macrophages. Science (Wash. DC). 260:547-549.
4. + T cells. Curr. Opin. Immunol. 7:367-374.
5. Dempsey, P.W., M.E.D. Allison, S. Akkaraju, C.C. Goodnow, and D.T. Fearon. 1996. C3d of complement as molecular adjuvant: bridging innate and acquired immunity. Science (Wash. DC). 271:348-350.
6. Colten, H.R. 1994. Drawing a double-edged sword. Nature (Lond.). 371:474-475.
7. Heyman, B., E.J. Wiersma, and T. Kinoshita. 1990. In vivo inhibition of the antibody response by a monoclonal complement receptor specific antibody. J. Exp. Med. 172:665-668.
8. Egwang, T.G., and A.D. Befus. 1984. The role of complement in the induction and regulation of immune responses. Immunology. 51:207-224.
9. Nicholson-Weller, A., and J.A. Halperin. 1993. Membrane signaling by complement C5b-9, the membrane attack complex. Immunol. Res. 12:244-257.
10. Karp, C.L., M. Wysocka, L.M. Wahl, J.M. Ahearn, P.J. Cuomo, B. Sherry, G. Trinchieri, and D.E. Griffin. 1996. Mechanism of suppression of cell-mediated immunity by measles virus. Science (Wash. DC). 273:228-231.
11. Yamamoto, S., C.J. Dunn, F. Capasso, D.A. Deporter, and D.A. Willoughby. 1974. Quantitative studies on cell-mediated immunity in the pleural cavity of guinea-pigs. J. Pathol. 117:65-73.
12. Cochrane, C.G., H.J. Muller-Eberhard, and B.S. Aikin. 1970. Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J. Immunol. 105:55-69.
13. Askenase, P.W. 1993. Effector and regulatory mechanisms in delayed-type hypersensitivity (DTH). In Allergy: Principles and Practice, 4th edition. E. Middleton, Jr., C.E. Reed, E.F. Ellis, and N.F. Atkinson, editors. C.V. Mosby Co., St. Louis, MO. 362-389.
14. Van Loveren, H., R. Meade, and P.W. Askenase. 1983. An early component of delayed-type hypersensitivity mediated by T cells and mast cells. J. Exp. Med. 157:1604-1617.
15. Geba, G.P., W. Ptak, G.M. Anderson, V. Paliwal, R.E. Ratzlaff, J. Levin, and P.W. Askenase. 1996. Delayed-type hypersensitivity in mast cell deficient mice: dependence on platelets for expression of contact sensitivity. J. Immunol. 157: 557-565.
16. Matsuda, H., G.P. Geba, and P.W. Askenase. 1997. Human platelets can initiate contact sensitivity through serotonin release mediated by IgE. J. Immunol. 158:2891-2897.
17. Ameisen, J.-C., R. Meade, and P.W. Askenase. 1989. A new interpretation of the involvement of serotonin in delayed-type hypersensitivity: serotonin-2 receptor antagonists inhibit contact sensitivity by an effect on T cells. J. Immunol. 142: 3171-3179.
18. Aune, T.M., H.W. Golden, and K.M. McGrath. 1994. Inhibitors of serotonin synthesis and antagonists of serotonin 1A receptors inhibit T lymphocyte function in vitro and cell-mediated immunity in vivo. J. Immunol. 153:489-498.
19. Fong, T.A.T., and T.R. Mosmann. 1989. The role of IFN-γ in delayed-type hypersensitivity mediated by Th1 clones. J. Immunol. 143:2887-2893.
20. Piguet, P.f., G.E. Grau, C. Hauser, and P. Vassalli. 1991. Tumor necrosis factor is a critical mediator in hapten-induced irritant and contact hypersensitivity reactions. J. Exp. Med. 173:673-679.
21. Schwartz, A., C. Kronke, F. Trautinger, Y. Aragane, P. Neuner, T.A. Luger, and T. Schwartz. 1993. Pentoxifylline suppresses irritant and contact hypersensitivity reactions. J. Investig. Dermatol. 101:549-552.
22. Bernhagen, J., M. Bacher, T. Calandra, C.N. Metz, S.B. Doty, T. Donnelly, and R. Bucala. 1996. An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J. Exp. Med. 183: 277-282.
23. Tsuji, R.F., J. Magae, K. Nagai, and M. Yamasaki. 1992. A novel in vivo screening method for immunomodulating substances: development of an assay system. Biosci. Biotechnol. Biochem. 56:1497-1498.
24. Tsuji, R.F., M. Uramoto, H. Koshino, N.M. Tsuji, J. Magae, K. Nagai, and M. Yamasaki. 1992. Preferential suppression of delayed-type hypersensitivity by L-156,602, a C5a receptor antagonist. Biosci. Biotechnol. Biochem. 56:1686-1689.
25. Tsuji, R.F., J. Magae, K. Nagai, and M. Yamasaki. 1992. Effects of L-156,602, a C5a receptor antagonist, on mouse experimental models of inflammation. Biosci. Biotechnol. Biochem. 56:2034-2036.
26. Tsuji, R.F., J. Yamakoshi, M. Uramoto, H. Koshino, M. Saito, M. Kikuchi, and T. Masuda. 1995. Anti-inflammatory effects and specificity of L-156,602: comparison of effects on concanavalin A and zymosan-induced footpad edema, and contact sensitivity response. Immunopharmacology. 29:79-87.
27. Hensens, O.D., R.P. Borris, L.R. Koupal, C.G. Caldwell, S.A. Currie, A.A. Haidri, C.F. Homnick, S.S. Honeycutt, S.M. Lindenmayer, C.D. Schwartz, et al. 1991. L-156,602, a C5a antagonist with a novel cyclic hexadepsipeptide structure from Streptomyces sp. MA6348. J. Antibiot. (Tokyo). 44:249-254.
28. Frank, M.M., and L.F. Fries. 1991. The role of complement in inflammation and phagocytosis. Immunol. Today. 12:322-326.
29. Hugli, T.E., and J. Müller-Eberhard. 1978. Anaphylatoxins: C3 and C5a. Adv. Immunol. 26:1-53.
30. Hugli, T.E. 1981. Structural basis for anaphylatoxin and chemotactic functions of C3a, C4a and C5a. Crit. Rev. Immunol. 1:321-366.
31. Meuer, S., U. Ecker, U. Hadding, and D. Bitter-Suermann. 1981. Platelet-serotonin release by C3a and C5a: two independent pathways of activation. J. Immunol. 126:1506-1509.
32. Tsuji, R.F., M. Kikuchi, and P.W. Askenase. 1996. Possible involvement of C5/C5a in the efferent and elicitation phases of contact sensitivity. J. Immunol. 156:4644-4650.
33. Piddlesden, S.J., M.K. Storch, M. Hibbs, A.M. Freeman, H. Lassmann, and B.P. Morgan. 1994. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J. Immunol. 152:5477-5484.
34. Mulligan, M.S., C.G. Yeh, A.R. Rudolph, and P.A. Ward. 1992. Protective effects of soluble CR1 in complement-and neutrophil-mediated tissue injury. J. Immunol. 148:1479-1485.
35. Weisman, H.F., T. Bartow, M.K. Leppo, H.C. Marsh, G.R. Carson, M.F. Concino, M.P. Boyle, K.H. Roux, M.L. Weisfeldt, and D.T. Fearon. 1990. Soluble human complement receptor type I: in vivo inhibitor of complement suppressing post-ischemia myocardial inflammation and necrosis. Science (Wash. DC). 249:146-151.
36. Wang, Y., S.A. Rollins, J.A. Madri, and L.A. Matis. 1995. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl. Acad. Sci. USA. 92:8955-8959.
37. Wang, Y., Q. Hu, J.A. Madri, S.A. Rollins, A. Chodera, and L.A. Matis. 1996. Amelioration of lupus-like autoimmune disease in NZB/W F1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc. Natl. Acad. Sci. USA. 93:8563-8568.
38. Askenase, P.W., B.J. Hayden, and R.K. Gershon. 1975. Augmentation of delayed-type hypersensitivity by dose of cytoxan which do not affect antibody responses. J. Exp. Med. 141:697-702.
39. Churchill, W.H., Jr., R.M. Weintraub, T. Borsos, and H.J. Rapp. 1967. Mouse complement: the effect of sex hormones and castration on two of the late-acting components. J. Exp. Med. 125:657-672.
40. Lewis, E., and J.L. Turk. 1975. Comparison of the effect of various antisera and cobra venom factor on inflammatory reactions in guinea-pig skin. I. Non-specific inflammation due to the intradermal injection of turpentine. J. Pathol. 115:97-109.
41. Kitamura, D., J. Roes, R. Kühn, and K. Rajewsky. 1991. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobin μ chain gene. Nature (Lond.). 350:423-426.
42. Grabbe, S., M. Steinert, K. Mahnke, A. Schwartz, T.A. Luger, and T. Schwarz. 1996. Dissection of antigenic and irritative effects of epicutaneously applied haptens in mice. Evidence that not the antigenic component but nonspecific proinflammatory effects of haptens determine the concentration-dependent elicitation of allergic contact dermatitis. J. Clin. Invest. 98:1158-1164.
43. Colten, H.R., R.C. Strunk, D.H. Perlmutter, and F.S. Cole. 1986. Regulation of complement protein biosynthesis in mononuclear phagocytes. Ciba Found. Symp. 118:141-154.
44. Johnson, E., and G. Hetland. 1988. Mononuclear phagocytes have the potential to synthesize the complete functional complement system. Scand. J. Immunol. 27:489-493.
45. Garred, P., G. Hetland, T.E. Mollnes, and G. Stoervold. 1990. Synthesis of C3, C5, C6, C7, C8 and C9 human fibroblasts. Scand. J. Immunol. 32:555-560.
46. Johnson, E., and G. Hetland. 1991. Human umbilical vein endothelial cells synthesize functional C3, C5, C6, C8 and C9 in vitro. Scand. J. Immunol. 33:667-671.
47. Petit, J.-C. 1980. Resistance to listeriosis in mice that are deficient in the fifth component of complement. Infect. Immun. 27:61-67.
48. + T cells during the elicitation of contact hypersensitivity. J. Investig. Dermatol. 107:360-366.
49. Sims, P.J., and T. Wiedmer. 1991. The response of human platelets to activated components of the complement system. Immunol. Today. 12:338-342.
50. Foreman, K.E., A.A. Vaporciyan, B.K. Bonish, M.L. Jones, K.L. Johnson, M.M. Glovsky, S.M. Eddy, and P.A. Ward. 1994. C5a-induced expression of P-selectin in endothelial cells. J. Clin. Invest. 94:1147-1155.
51. Kilgore, K.S., J.P. Shen, B.F. Miller, P.A. Ward, and J.S. Warren. 1995. Enhancement by complement membrane attack complex of tumor necrosis factor-α-induced endothelial cell expression of E-selectin and ICAM-1. J. Immunol. 155: 1434-1441.
52. Vaporciyan, A.A., M.S. Mulligan, J.S. Warren, P.A. Barton, M. Miyasaka, and P.A. Ward. 1995. Up-regulation of lung vascular ICAM-1 in rats is complement dependent. J. Immunol. 155:1442-1449.
53. Mulligan, M.S., E. Schmid, G.O. Till, T.E. Hugli, H.P. Friedl, R.A. Roth, and P.A. Ward. 1997. C5a-dependent up-regulation in vivo of lung vascular P-selectin. J. Immunol. 158:1857-1861.
54. Gerard, C.G., D.E. Chenoweth, and T.E. Hugli. 1979. Molecular aspects of the serum chemotactic factors. J. Reticuloendothel. Soc. 26:711-718.
55. Hopken, U.E., B. Lu, N.P. Gerard, and C. Gerard. 1996. The C5a chemoattractant receptor mediates mucosal defence to infection. Nature (Lond.). 383:86-89.